Heart BMJ

MARCH 26, 2025

Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. fold higher risk of heart failure with preserved ejection fraction (95% CI 1.30

Aortic valve 52

Aortic valve Myocardial Infarction Preserved Ejection Fraction Heart Failure 52

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 However, mortality rate is greater in HF cases developing >3 days following MI compared with less than or equal to 3 days after MI.

Myocardial Infarction 52

Myocardial Infarction Preserved Ejection Fraction Heart Failure Aortic valve 52

European Journal of Heart Failure

FEBRUARY 5, 2025

Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Atrial Fibrillation 40

European Journal of Heart Failure

DECEMBER 28, 2023

Abstract Aims Preventive strategies for heart failure (HF) with preserved ejection fraction (HFpEF) include pharmacotherapies and lifestyle modifications. All had no evidence of HF or myocardial infarction prior to completion of the ETT. years and 43,179 women; mean age 55.0±8.9 years) year apart.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Article 40

Open Heart

JANUARY 8, 2024

The secondary outcomes were composite major adverse cardiac events (MACE) (study defined), myocardial infarction (MI), stroke, cardiac death, sudden death, the development of symptoms, heart failure hospitalisations and major bleeding. The primary outcome was all-cause mortality. to 1.1), I 2 =31%, p=0.09).

Aortic valve 98

Aortic valve Aortic Preserved Ejection Fraction Stenosis 98

Circulation

OCTOBER 13, 2023

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

Circulation: Heart Failure

NOVEMBER 25, 2024

Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century. The use of MRAs has been limited due to excessive concern about hyperkalemia.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40